Renaissance Capital logo

Molecular Partners Priced, Nasdaq: MOLN

Swiss biotech developing engineered protein therapies for COVID-19 and cancers.

Industry: Health Care

Latest Trade: $19.76 0.00 (0.0%)

First Day Return: -7.5%

Return from IPO: -7.0%

Industry: Health Care

We are a clinical stage biopharmaceutical company applying our pioneering DARPinĀ® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class of drugs with broad therapeutic applications that may overcome many of the limitations of conventional protein and antibody-based therapeutics. DARPin proteins are designed using natural repeat proteins, a class of binder proteins that are common in humans and most other species. Our DARPin product candidates have been extensively tested in preclinical studies and clinical trials, including in approximately 2,000 patients in ophthalmology, infectious disease (SARS-CoV-2) and oncology, and have been observed to be highly active, present differentiated product profiles and be generally well-tolerated.
more less
IPO News for Molecular Partners
more
IPO Data
IPO File Date 04/22/2021
Offer Price $21.25
Price Range $21.25 - $21.25
Offer Shares (mm) 3.0
Deal Size ($mm) $64
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/15/2021
Offer Price $21.25
Price Range $21.25 - $21.25
Offer Shares (mm) 3.0
Deal Size ($mm) $64
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Zurich, Switzerland
Founded 2004
Employees 152
Website www.molecularpartners.com